Veru rises as combo drug shows fewer side effects than semaglutide alone in trial

Shares of weight-loss drug developer of Veru VERU.O rise 46% to 74 cents premarket

VERU says combination of its experimental drug, enobosarm, and semaglutide resulted in fewer gastrointestinal side effects such as diarrhea and nausea in mid-stage trial, compared with semaglutide alone

Combo drug met main goal of mid-stage trial earlier this year

Patients taking enobosarm 3mg with semaglutide saw 99% loss of fat while preserving lean muscle mass, co says

VERU has requested meeting with U.S. FDA to discuss next steps for enobosarm, including potential late-stage trial

As of last close, stock down 21.8% YTD